நோயாளி பாதுகாப்பு அட்டை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோயாளி பாதுகாப்பு அட்டை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோயாளி பாதுகாப்பு அட்டை Today - Breaking & Trending Today

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , Lisa Taylor , Mjamesf Howard , John Orloff , Kevin Oneil , Department Of Neurology , Head Of Research Development At Alexion , University Of North Carolina , Alexion Pharmaceuticals Inc , European Union , Myasthenia Gravis Foundation Of America , Myasthenia Gravis Activities , Daily Living Profile , Professor James , North Carolina , Chapel Hill , Executive Vice President , North America , Myasthenia Gravis Foundation , Clinical Classification Class , About Generalized Myasthenia Gravis , Paroxysmal Nocturnal Hemoglobinuria , Hemolytic Uremic Syndrome , Patient Safety Card , Prescribing Information , Medication Guide ,

Alexion Provides Update on Phase 3 Study of ULTOMIRIS (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).
adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS). ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
It is not known if ULTOMIRIS is safe and effective in children with PNH.
It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ULTOMIRIS?
ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. ....

United States , United Kingdom , John Orloff , Megan Goulart , Head Of Research Development At Alexion , Corporate Communications , European Union , Cambridge University Hospitals , Alexion Pharmaceuticals Inc , Alexion Pharmaceuticals , Executive Vice President , Paroxysmal Nocturnal Hemoglobinuria , Hemolytic Uremic Syndrome , Patient Safety Card , Prescribing Information , Medication Guide , Quarterly Report , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஜான் ஆர்லாஃப் , மேகன் கோஉலர்த் , தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி இல் அலெக்சியன் , பெருநிறுவன தகவல்தொடர்புகள் , ஐரோப்பிய தொழிற்சங்கம் , கேம்பிரிட்ஜ் பல்கலைக்கழகம் மருத்துவமனைகள் , அலெக்சியன் மருந்துகள் இன்க் ,

Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

Press release content from Business Wire. The AP news staff was not involved in its creation.
Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
January 13, 2021 GMT
BOSTON (BUSINESS WIRE) Jan 13, 2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the decision to pause further enrollment in the global Phase 3 study of ULTOMIRIS ® (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventilation. This decision is based on the recommendation of an independent data monitoring committee (IDMC), following their review of data from a pre-specified interim analysis. The IDMC recommended that additional enrollment be paused, pending further analysis of the data, due to lack of efficacy when ULTOMIRIS was added to best supportive care, compared to best supportive care alone. There were no new safety findings observed. The study will continue for patients already enrolled, ....

United States , United Kingdom , John Orloff , Megan Goulart , Chris Stevo , Head Of Research Development At Alexion , European Union , Cambridge University Hospitals , Alexion Pharmaceuticals Inc , Executive Vice President , Paroxysmal Nocturnal Hemoglobinuria , Hemolytic Uremic Syndrome , Patient Safety Card , Prescribing Information , Medication Guide , Quarterly Report , Alexion Pharmaceuticals , Business Wire , Public Health , Pregnancy And Childbirth , Products And Services , Coronavirus Pandemic , Product Testing , Diagnosis And Treatment , Sexual And Reproductive Health , Pharmaceutical Manufacturing ,